Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 46(1); 2014 > Article
Original Article The Role of Radiotherapy in the Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Taek-Keun Nam, MD1, Jae-Sook Ahn, MD2, Yoo-Duk Choi, MD3, Jae-Uk Jeong, MD1, Yong-Hyeob Kim, MD1, Mee Sun Yoon, MD1, Ju-Young Song, PhD1, Sung-Ja Ahn, MD1, Woong-Ki Chung, MD1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(1):33-40.
DOI: https://doi.org/10.4143/crt.2014.46.1.33
Published online: January 15, 2014

1Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.

2Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.

3Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.

Correspondence: Woong-Ki Chung, MD. Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, 322 Seoyang-ro, Hwasun 519-763, Korea.
Tel: 82-61-379-7200, Fax: 82-61-379-7249, wkchung@jnu.ac.kr
• Received: April 8, 2013   • Accepted: May 24, 2013

Copyright © 2014 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 13,039 Views
  • 101 Download
  • 19 Web of Science
  • 17 Crossref
  • 20 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    To assess radiotherapy for patients with early stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma with respect to survival, treatment response, and complications.
  • Materials and Methods
    Enrolled into this study were 48 patients diagnosed with gastric MALT lymphoma from January 2000 to September 2012. Forty-one patients had low grade and seven had mixed component with high grade. Helicobacter pylori eradication was performed in 33 patients. Thirty-four patients received radiotherapy alone. Ten patients received chemotherapy before radiotherapy, and three patients underwent surgery followed by chemotherapy and radiotherapy. One patient received surgery followed by radiotherapy. All patients received radiotherapy of median dose of 30.6 Gy.
  • Results
    The duration of follow-up ranged from 6 to 158 months (median, 48 months). Five-year overall survival and cause-specific survival rates were 90.3% and 100%. All patients treated with radiotherapy alone achieved pathologic complete remission (pCR) in 31 of the low-grade and in three of the mixed-grade patients. All patients treated with chemotherapy and/or surgery prior to radiotherapy achieved pCR except one patient who received chemotherapy before radiotherapy. During the follow-up period, three patients developed diffuse large B-cell lymphoma in the stomach, and one developed gastric adenocarcinoma after radiotherapy. No grade 3 or higher acute or late complications developed. One patient, who initially exhibited gastroptosis, developed mild atrophy of left kidney.
  • Conclusion
    These findings indicate that a modest dose of radiotherapy alone can achieve a high cure rate for low-grade and even mixed-grade gastric MALT lymphoma without serious toxicity. Patients should be carefully observed after radiotherapy to screen for secondary malignancies.
  • Key words: Stomach, Marginal zone B-cell lymphoma, Radiotherapy
Non-Hodgkin's lymphoma is the most common hematologic malignancy, accounting for approximately 43% of all hematologic malignancies in Korea [1]. In the third nationwide study reported in 2011, extranodal marginal zone B-cell lymphoma (MZBCL) of mucosa-associated lymphoid tissue (MALT) accounted for 19.0% of non-Hodgkin's lymphomas, with the second leading frequency, following diffuse large B-cell lymphoma (DLBCL), which represents 42.7% of cases [2]. This study reported that Korea has higher incidence rates of extranodal MZBCL compared with other Asian countries, ranging from 2.5% to 8.5% [2]. Another study of a single institution in Korea further reported that the most affected sites of extranodal MALT lymphoma are the stomach (49%), eye (36%), thyroid (4.9%), and small intestine (2.5%) [3].
Helicobacter pylori is an important causative organism for development of gastric MALT lymphoma [4], with a positive rate of approximately 90% in early stage gastric MALT lymphoma patients at diagnosis [5]. After H. pylori eradication, a remission rate of approximately 80% can be achieved in Ann Arbor stage I patients [6], but only 45% to 56% in stage II [5,7]. As may be expected, H. pylori eradication therapy alone results in a much lower response rate in patients without H. pylori infection [5]. However, the most appropriate therapeutic strategy for gastric MALT-lymphoma in patients who do not respond to H. pylori eradication or without H. pylori infection is unclear. Since randomized studies have not been performed, refractory gastric MALT lymphoma is generally treated with one or more conventional oncologic modalities, including chemotherapy, radiotherapy (RT), surgery, and more recently, immunotherapy. Unfortunately, the heterogeneity of the oncologic treatments used and the generally small sample sizes in different studies make it difficult to interpret their efficacy.
As a salvage treatment regardless of H. pylori infection status, RT is highly effective, with a superior remission rate compared to chemotherapy (97.3% vs. 85.3%, p=0.007) and surgery (97.3% vs. 92.5%, p=0.2) [7]. Given that gastric MALT lymphoma has a natural history of slow progression, remaining confined to the stomach even over several years, local field RT could be an effective treatment modality with organ preservation. However, thus far, only a few studies with small numbers of patients have reported safety and efficacy of RT for the treatment of gastric MALT lymphoma in Korea [8].
In this study, we performed a retrospective analysis to assess the role of RT as a primary or salvage treatment in patients with early stage gastric MALT lymphoma diagnosed at our institution with respect to survival, treatment response, and complications.
1. Patient enrollment
From January 2000 to September 2012, 50 patients with the diagnosis of gastric MALT lymphoma were treated with RT. Two patients lost to follow-up after RT were excluded from the evaluation. The remaining 48 patients were enrolled in this study.
2. Diagnosis and staging
All patients underwent diagnostic endoscopy and had pathologic confirmation of their diagnosis at local clinics or our institution. Although there are some differences between the cases, the main histologic features are a diffuse infiltration of lymphoid cells with lymphoepithelial lesion. The lymphoid cells showed centrocyte-like morphology, pale cytoplasm with small to medium sized, slightly irregularly shaped nuclei containing dispersed chromatin. Scattered large cells resembling centroblasts are present. Occasionally, plasma cells are also present. The lymphoid cells are immunoreactive for CD20+, CD5-, CD10-, and cyclin D1-, histologically consistent with the low-grade MALT lymphoma. Disease stage was determined based on the Ann Arbor Classification of Extranodal Lymphoma (modified by Musshoff) [6]. Work-up studies comprised patient medical history including duration and presence of local or systemic symptoms, physical examination, laboratory tests such as complete blood counts, peripheral blood smear, lactate dehydrogenase, β2-microglobulin levels, and evaluation of renal and liver function. Other staging procedures included bone marrow biopsy, chest radiographs, abdominal and pelvic computed tomography scan, and/or gastric endoscopic ultrasonography (EUS). H. pylori infection was determined by histological examination, rapid urease test, urea breath test, and/or serum anti-H. pylori immunoglobulin G antibody.
3. Treatment
Anti-H.pylori antibiotic therapy using lansoprazole, clarithromycin, and amoxicillin was administered to 30 of 31 patients with H. pylori infection and to three of 13 patients without H. pylori infection for 7 or 14 days. Four patients without information regarding H. pylori infection status did not receive H. pylori eradication. Thirty-four of the 48 patients received RT alone. Ten patients received chemotherapy before RT with one of three regimens, including cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), rituximab-CHOP (R-CHOP), or fludarabine, mitoxantrone, and dexamethasone (FND). Three patients underwent surgery followed by chemotherapy and RT. One patient received surgery followed by RT. All patients received RT of median total dose of 30.6 Gy (range, 30.6 to 45.0 Gy), with a fraction size of 1.8 Gy for 3.5 to 5 weeks. Patients were treated primarily with opposed anterior and posterior two fields, or occasionally three or four fields targeting the stomach and perigastric lymph nodes with additional margins using two-dimensional (Fig. 1A) or three-dimensional conformal RT (Fig. 1B), with or without respiratory gating. All patients were treated in the supine position with an empty stomach by a 6- or 10-MV X-ray of linear accelerator on an outpatient basis.
4. Follow-up and statistical analysis
Response assessment was performed every three months by gastroduodenoscopy, including gathering biopsy samples, until one year after completion of RT, and every six months thereafter. Pathologic complete remission (pCR) was defined as the total disappearance of clinical evidence for lymphoma and an absence of histologic evidence for lymphoma on biopsy specimens. In cases with complete remission, endoscopic examinations and biopsies were performed at regular intervals. Blood work, including a complete blood cell count and screening profile, was performed biannually for the first two years, and thereafter annually. Chest X-ray and computed tomography (CT) scans of the abdomen and pelvis were also performed annually. The overall survival (OS), cause-specific survival (CSS), and event-free survival (EFS) rates were analyzed by Kaplan-Meier methods. OS was measured from the date of start of RT to death from any cause, and CSS was measured from the date of start of RT to the date of death due to gastric MALT lymphoma. EFS was measured from the date of start of RT to the date of death from any cause, diagnosis of relapse of MALT lymphoma or transformation to a DLBCL. Toxicity was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE v.4.0).
1. Patient clinical features
Forty-one patients were diagnosed with low-grade MALT lymphoma, and the remaining seven patients had low-grade MALT lymphoma mixed with high-grade transformation components (Table 1). Forty of these patients (83.3%) had an Eastern Cooperative Oncology Group (ECOG) performance score of 0. The median age of the patients was 53 years with a range of 45 to 73. Thirty-two patients (66.7%) had lesions located mainly in the mid to the lower stomach. Two patients had additional involvement of the duodenum (stage IIE2). Twenty-five patients (61.0%) had ulcerative or infiltrative endoscopic type tumors. Thirteen patients (27.1%) also exhibited intestinal metaplasia. H. pylori infection was noted in 31 patients (64.6%).
2. Treatment modality according to pathologic grade
Among the 41 patients with low-grade MALT lymphoma (Fig. 2A), 31 patients underwent RT alone. Twenty-three of these patients had H. pylori infection and underwent H. pylori eradication therapy. Of the 23 patients receiving eradication, 14 patients showed persistent disease after eradication, and the remaining nine patients underwent RT immediately after eradication without response evaluation. Another seven out of the 41 patients with low-grade MALT lymphoma underwent chemotherapy prior to RT. Of these seven, six patients showed persistent disease after H. pylori eradication, while the other patient did not undergo eradication. Of the seven patients who received chemotherapy prior to RT, five showed complete remission after chemotherapy, and two showed partial remission. Another two out of the 41 patients, who did not initially undergo H. pylori eradication, underwent a wedge resection plus chemotherapy prior to RT. One remaining patient did not undergo H. pylori eradication, but had a total gastrectomy prior to RT. Median dose of RT in these 41 low grade patients was 30.6 Gy (range, 30.6 to 43.2 Gy).
Among the seven mixed grade patients (Fig. 2B), three patients had RT alone, two immediately following H. pylori eradication without response evaluation and one without H. pylori eradication. Three other mixed grade patients had chemotherapy plus RT. Two of these patients showed persistent disease after H. pylori eradication, while the other patient did not undergo eradication. Of the three patients who received chemotherapy prior to RT, two showed complete remission after chemotherapy. The other patient, who had also shown persistent tumor after initial eradication, showed partial remission. The remaining one patient with mixed grade MALT lymphoma, who also did not undergo H. pylori eradication, underwent a total gastrectomy plus chemotherapy followed by RT. The median dose of RT in these seven mixed grade patients was 37.8 Gy (range, 30.6 to 45.0 Gy)
3. Treatment outcome
The follow-up period for all patients ranged from 6 to 158 months, with a median of 48 months. The 5-year OS rate was 90.3%, CSS was 100%, and EFS was 85.2%. All thirty-four patients, 31 of low-grade and 3 of mixed-grade, treated with RT alone achieved pCR. In 10 patients who received chemotherapy prior to RT, five of seven patients with low grade and two of three patients with mixed grade achieved complete remission to chemotherapy and received consolidative involved field RT. The remaining three of 10 patients who exhibited a partial response received salvage RT, two of whom achieved a complete response. One showed a persistent tumor combined with newly developed a gastric DLBCL. The other four patients who received surgery initially, with or without chemotherapy, received consolidative RT.
Among all patients, three patients died without evidence of disease, one from renal insufficiency at 56 months, one from intracranial hemorrhage at 12 months, and one from an unknown cause at 16 months post-RT. During the follow-up period, three patients developed second malignancies (Table 2). One patient with initially low-grade lymphoma showed persistent tumor combined with DLBCL three months after chemotherapy and RT. This patient initially underwent H. pylori eradication, but had persistent disease. Following eradication, she received three cycles of FND chemotherapy, but responded only partially. The patient then received salvage RT, but showed persistent tumor mixed with DLBCL. Thereafter, the patient was salvaged completely with four cycles of R-CHOP augmented with four cycles of Rituximab and is alive without disease at 31 months after RT. The second patient had a DLBCL 38 months after completion of RT for initial low-grade MALT lymphoma. She received eight cycles of R-CHOP for newly developed DLBCL and has no evidence of disease at 64 months after RT. The third patient was diagnosed with gastric adenocarcinoma and bronchus-associated lymphoid tissue (BALT) lymphoma at 44 and 51 months after completion of RT for initial low-grade MALT lymphoma. This patient had endoscopic mucosal resection for gastric adenocarcinoma (pT1 lesion), but no further treatment for BALT and expired due to renal failure at 57 months after RT. Follow-up endoscopy study for all patients after RT revealed that 13 patients had H. pylori reinfection, of whom 11 received primary or secondary eradication. Five out of these 13 patients did not have a history of H. pylori infection originally.
4. Toxicity
Acute complications were grade 2 (n=31) or grade 1 (n=1) with complaints of nausea, vomiting, dyspepsia, anorexia, diarrhea, or abdominal pain. No grade 3 or higher complications developed either as acute or late complications. Late grade 2 complications developed in three patients with gastric erosion, erythematous gastritis, and gastric ulcer. One patient, who initially had gastroptosis, developed left kidney atrophy. Because of gastroptosis, an extremely large RT field size was used to cover the entire stomach such that the entire left kidney was included within the RT field (Fig. 1C). This patient had been diagnosed with early gastric adenocarcinoma treated with endoscopic mucosal resection and BALT lymphoma (no treatment) after RT completion as described above. However, she died due to renal insufficiency with Waldenström's macroglobulinemia and metabolic acidosis at 56 months post-RT. Her kidney disease was not due to prior RT because ultrasonography of both kidneys at 52 months after RT showed mild atrophic change of the left kidney, but normal echogenicity with an intact right kidney (Fig. 1D).
RT alone can be used to achieve complete remission for almost all low-grade gastric MALT lymphomas in cases that do not have H. pylori infection or in cases with persistent lymphoma after H. pylori eradication therapy [9-11]. A multicenter cohort study of a large number of patients with gastric MALT lymphoma reported that male gender, absence of H. pylori, location in proximal or multiple areas, non-superficial type, and advanced stage were independent predictors of resistance to H. pylori eradication therapy [5]. Among thirty-four patients treated by RT alone in our study, 25 patients received RT for the following reasons: persistent tumor after H. pylori eradication (n=14), without H. pylori eradication (n=8), and mixed grade (n=3) (Fig. 2A and B). The remaining nine patients were recommended to receive definitive RT immediately after H. pylori eradication because they had one or more factorsamong the following: submucosal or proper muscle layer involvement on EUS, diffuse gastric wall thickening or perigastric lymphadenopathy on abdominal CT. In this study, RT alone achieved pCR in all patients, including those with mixed grade, regardless of the above adverse predictors.
Gastric MALT lymphoma often is a result of H. pylori infection-associated chronic gastritis [4,12], with a positivity rate approximately 90% in early stage gastric MALT lymphoma patients at diagnosis [5]. In this study, the H. pylori infection rate was 64.6%, lower than the general infection rate, although four cases did not have information regarding H. pylori infection status. Those were likely to be H. pylori positive if a thorough examination had been done. Fourteen patients received chemotherapy and/or surgery prior to RT, due to persistent disease after H. pylori eradication or the absence of initial H. pylori eradication. Four patients in this study undertook initial surgery prior to RT, three of whom received chemotherapy postoperatively. At that time, RT was added with or without chemotherapy because these patients had surgical pathologic findings of either all layer involvement of stomach or perigastric lymph nodes metastasis. The era of performing RT on these patients was in the earlier half of this study, but later patients did not receive consolidative RT after curative surgery in gastric MALT lymphoma at our institution.
High-grade gastric lymphoma is observed in some patients at the long-term follow-up visit regardless of initial remission after H. pylori eradication [5,7]. Two patients developed DLBCL as a secondary malignancy during the follow-up period after RT. One of these patients, who had persistent MALT lymphoma after initial chemotherapy, developed DLBCL with still persistent MALT lymphoma even after salvage RT, while the other patient developed DLBCL after complete remission for MALT lymphoma after RT. These two patients were successfully salvaged by chemotherapy and were alive at the last follow-up. In a multicenter study for gastric MALT lymphoma, 8.8% of patients treated with H. pylori eradication were regarded as treatment failures, with transformation into DLBCL occurring in 24.3% of these patients [5]. Genetic aberrations such as p53 abnormalities or Bcl-6 over expression can occur in the transition from initial low-grade gastric MALT lymphomas to high-grade MALT lymphoma [12-14] or to DLBCL [15].
H. pylori infection is the strongest recognized risk factor for gastric adenocarcinoma, and much progress has been made in understanding the pathogenesis of this relationship [4,16,17]. In our study, one patient developed early gastric adenocarcinoma at 44 months and BALT lymphoma at 51 months after RT with complete remission of previous gastric MALT lymphoma. This patient did not have H. pylori infection before treatment, but was diagnosed with H. pylori infection upon follow-up endoscopy immediately after RT. There are published case reports regarding metachronous gastric MALT lymphoma and gastric adenocarcinoma [18,19]. Patients with Hodgkin's disease or non-Hodgkin's lymphomas appear to be at a higher risk of developing other cancers, and a high prevalence of secondary malignancies has been found in some gastric MALT lymphoma series [20,21]. However, there is little evidence to suggest that local RT alone is associated with an increased risk of secondary malignancies [22].
This study has two limitations. The first is that we included the seven patients diagnosed as MALT lymphoma mixed with high-grade component. World Health Organization recommended any MALT lymphoma with a partial high-grade component, whether it might be transformed from low-grade MALT lymphoma or not, should be classified as a DLBCL [23]. In the past, some pathologists have diagnosed this type as "transformation of a low-grade MALT lymphoma"or "high-grade MALT lymphoma," which might confuse a clinician in making treatment decisions. A study regarding the treatment of H.pylori positive gastric high-grade transformed MALT lymphoma reported that H. pylori eradication alone could achieve pCR rate of 64% [24]. In our study, we tried to point out that although we treated these seven patients with H. pylori eradication, RT, chemotherapy, or surgery either in combinations or alone, we could achieve pCR in three patients with mixed grade using RT alone. Further study with a larger sample is warranted to analyze the result of RT alone in mixed grade patients.
The second limitation is that some patients received consolidative RT even after achieving pCR using surgery and/or chemotherapy. Until recently, in the treatment of gastric MALT lymphoma, there was no consensus regarding standard treatment for the refractory tumor after H.pylori eradication or H. pylori negative tumor. Consolidative RT was added at that time because patients had one or more adverse predictors such as stage II or submucosal layer or deeper involvement. Now this treatment approach could be regarded as an over treatment and patients are no longer referred for consolidative RT after achieving pCR with chemotherapy or surgery in gastric MALT lymphoma at our institution.
The US National Comprehensive Cancer Network recommends H. pylori eradication as a first-line treatment for H. pylori-positive gastric MALT lymphoma and RT as a second-line treatment for H. pylori-negative or refractory lymphoma [25]. However, H. pylori eradication alone does not have as high a cure rate as RT in some patients, especially with proximal or multiple tumors, non-superficial type, advanced stage, chromosomal translocation t(11;18), or mixed with high grade component [5]. Conversely, research shows that RT can achieve complete remission regardless of these adverse factors [9-11]. The current treatment protocol for low-grade gastric MALT lymphoma at our institution is that patients who have adverse predictors as above are recommended for definitive RT preceded by H. pylori eradication, if H. pylori infection is present at the initial diagnosis. However, long-term follow-up is needed to screen for the development of secondary malignancy, and if H. pylori re-infection is diagnosed, it should be re-eradicated.
The findings from this study show that a modest dose of RT alone as a primary or salvage treatment can achieve a high cure rate for both low- and mixed-grade gastric MALT lymphoma without serious toxicity. Careful systematic observation should be performed after RT to screen for the development of H. pylori reinfection or secondary malignancy.

Conflict of interest relevant to this article was not reported.

  • 1. Park HJ, Park EH, Jung KW, Kong HJ, Won YJ, Lee JY, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol. 2012;47:28–38. PMID: 22479275ArticlePubMedPMC
  • 2. Kim JM, Ko YH, Lee SS, Huh J, Kang CS, Kim CW, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol. 2011;45:254–260. Article
  • 3. Hahn JS, Kim YS, Lee YC, Yang WI, Lee SY, Suh CO. Eleven-year experience of low grade lymphoma in Korea (based on REAL classification). Yonsei Med J. 2003;44:757–770. PMID: 14584090ArticlePubMed
  • 4. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am. 2005;89:313–344. PMID: 15656929ArticlePubMed
  • 5. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–513. PMID: 21890816ArticlePubMed
  • 6. Ahmad A, Govil Y, Frank BB. Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol. 2003;98:975–986. PMID: 12809817ArticlePubMed
  • 7. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105–110. PMID: 19631287ArticlePubMed
  • 8. Park HC, Park W, Hahn JS, Kim CB, Lee YC, Noh JK, et al. Low grade MALT lymphoma of the stomach: treatment outcome with radiotherapy alone. Yonsei Med J. 2002;43:601–606. PMID: 12402372ArticlePubMed
  • 9. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916–1921. PMID: 9586910ArticlePubMed
  • 10. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008;87:405–411. PMID: 18343513ArticlePubMed
  • 11. Okada H, Takemoto M, Kawahara Y, Nasu J, Takenaka R, Kawano S, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion. 2012;86:179–186. PMID: 22907329ArticlePubMed
  • 12. Yoshino T, Akagi T. Gastric low-grade mucosa-associated lymphoid tissue lymphomas: their histogenesis and high-grade transformation. Pathol Int. 1998;48:323–331. PMID: 9704338ArticlePubMed
  • 13. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood. 1995;86:4587–4593. PMID: 8541549ArticlePubMed
  • 14. Omonishi K, Yoshino T, Sakuma I, Kobayashi K, Moriyama M, Akagi T. bcl-6 protein is identified in high-grade but not low-grade mucosa-associated lymphoid tissue lymphomas of the stomach. Mod Pathol. 1998;11:181–185. PMID: 9504689PubMed
  • 15. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:2490–2497. PMID: 16636337ArticlePubMed
  • 16. Nguyen LT, Uchida T, Murakami K, Fujioka T, Moriyama M. Helicobacter pylori virulence and the diversity of gastric cancer in Asia. J Med Microbiol. 2008;57(Pt 12):1445–1453. PMID: 19018013ArticlePubMed
  • 17. The EUROGAST Study GroupAn international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341:1359–1362. PMID: 8098787ArticlePubMed
  • 18. Hasegawa N, Kato K, Yamada K, Morita K, Kuroiwa M, Ito H, et al. Early-stage gastric adenocarcinoma: revealed after anti-Helicobacter pylori therapy of MALT lymphoma. Gastrointest Endosc. 2001;53:495PMID: 11275894ArticlePubMed
  • 19. Seo DB, Kwon KS, Park HS, Lee DH, Kim HG, Shin YW, et al. Metachronous gastric MALT lymphoma and early gastric cancer: a case report. Korean J Gastroenterol. 2007;49:245–250. PMID: 17464170PubMed
  • 20. Zucca E, Pinotti G, Roggero E, Comi MA, Pascarella A, Capella C, et al. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol. 1995;6:726–728. PMID: 8664197ArticlePubMed
  • 21. Montalban C, Castrillo JM, Lopez-Abente G, Abraira V, Serrano M, Bellas C, et al. Other cancers in patients with gastric MALT lymphoma. Leuk Lymphoma. 1999;33:161–168. PMID: 10194134ArticlePubMed
  • 22. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897–906. PMID: 12610191ArticlePubMed
  • 23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193–207. PMID: 10697278ArticlePubMed
  • 24. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–1353. PMID: 16174856ArticlePubMed
  • 25. National Comprehensive Cancer NetworkNCCN clinical practice guidelines on oncology: Non-Hodgkin's Lymphomas, version 3.2012 [Internet]. Fort Washington: National Comprehensive Cancer Network; c2012. cited 2012 Oct 20Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
Fig. 1
(A) Simulation images of two-dimensional plan for radiotherapy with anterior-posterior opposing two fields including stomach and regional lymphatic area. (B) Three-dimensional plan with dose distribution shown on adjacent visceral organs. (C) Patient with gastroptosis, which required the radiotherapy field to be much larger than usual, covering entire left kidney. (D) Follow-up abdomen computed tomography showing mild atrophy with normal parenchymal density of left kidney.
crt-46-33-g001.jpg
Fig. 2
Breakdown of treatment modality by pathologic grade. Low grade (A) and low and high grade mixed (B). H., Helicoboacter; dCRT, definitive radiotherapy; PD, persistent disease; sRT, salvage radiotherapy; CTx, chemotherapy; CR, complete remission; cRT, consolidative radiotherapy; S, surgery.
crt-46-33-g002.jpg
Table 1
Patient characteristics
Patients characteristic No. of patients (%)
Age (yr) 53 (25-85)
Gender
 Male vs. Female 25 (52.1) vs. 23 (47.9)
ECOG performance score
 0 40 (83.3)
 1 8 (16.7)
Helicobacter pylori infection
 Positive 31 (64.6)
 Negative 13 (27.1)
 Unknown 4 (8.3)
Dominant site of lesion
 Proximal 16 (33.3)
 Distal two-thirds 32 (66.7)
Dominant endoscopic type
 Exophytic 23 (39.0)
 Ulcerative 25 (61.0)
Histologic grade
 Low 41 (85.4)
 Mixed with high grade component 7 (14.6)
Clinical stage
 IE 37 (77.1)
 IIE 11 (22.9)
Other location
 Stomach only 37 (77.1)
 Stomach+perigastric lymph nodes 9 (18.8)
 Stomach+duodenum 2 (4.1)

ECOG, Eastern Cooperative Oncology Group.

Table 2
Patients who developed secondary malignances during the follow-up period
Characteristic Case 1 Case 2 Case 3
Age (yr) 78 40 52
Gender Female Male Female
Grade Low Low Low
Stage IIE IE IE
Initial Helicobacter pylori infection Yes Yes No
H. pylori eradication Yes Yes No
Oncologic treatment FND #3
+ RT 30.6 Gy		 RT 30.6 Gy RT 30.6 Gy
Response PD CR CR
Second malignancy DLBCL+MALT DLBCL EGC/BALT
Interval from RT to diagnosis of secondary malignancy 3 mo 38 mo 44/51 mo
Salvage treatment R-CHOP #4 +
+ rituximab augmentation #4		 R-CHOP #8 EMR/no treatment
Final follow-up status NED at 31 mo NED at 64 mo Dead without MALT at 57 mo

FND, fludarabine, mitoxantrone, dexamethasone; RT, radiotherapy; PD, persistent disease; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; EGC, early gastric adenocarcinoma; BALT, bronchus-associated lymphoid tissue; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; EMR, endoscopic mucosal resection; NED, no evidence of disease.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist’s Point of View
      Tamara Matysiak-Budnik, Kateryna Priadko, Céline Bossard, Nicolas Chapelle, Agnès Ruskoné-Fourmestraux
      Cancers.2023; 15(15): 3811.     CrossRef
    • Magnetic Resonance Imaging-Guided Radiation Therapy for Early-Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
      Neris Dincer, Gamze Ugurluer, Gorkem Gungor, Teuta Zoto Mustafayev, Banu Atalar, Enis Ozyar
      Cureus.2022;[Epub]     CrossRef
    • Development and Validation of a Prognostic Nomogram for Gastric Marginal Zone Lymphoma: a Surveillance, Epidemiology and End Results-based population Study
      Mingliang Wang, Cheng Wu, Yida Lu, Xin Xu, Huizhen Wang, Youliang Wu, Xiaodong Wang, Yongxiang Li
      Future Oncology.2021; 17(5): 529.     CrossRef
    • Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma
      Laurent Quéro, Mouna Labidi, Marc Bollet, Côme Bommier, Sophie Guillerm, Christophe Hennequin, Catherine Thieblemont
      World Journal of Gastrointestinal Oncology.2021; 13(10): 1453.     CrossRef
    • Second Cancers in a Patient with Gastric MALT Lymphoma
      Lucy Navsaria, Alfonso Badillo, Michael Wang
      Case Reports in Medicine.2020; 2020: 1.     CrossRef
    • The Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma using Radiotherapy
      Aswin Nagarajan, Arun Sakthivelu, Alexander John, Ramya Ravichandar
      Indian Journal of Medical and Paediatric Oncology.2020; 41(04): 559.     CrossRef
    • Favorable radiation field decrease in gastric marginal zone lymphoma
      Gabriele Reinartz, Regina P. Pyra, Georg Lenz, Rüdiger Liersch, Georg Stüben, Oliver Micke, Kay Willborn, Clemens F. Hess, Andreas Probst, Rainer Fietkau, Ralf Jany, Jürgen Schultze, Christian Rübe, Carsten Hirt, Wolfgang Fischbach, Martin Bentz, Severin
      Strahlentherapie und Onkologie.2019; 195(6): 544.     CrossRef
    • Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma
      Anne-Laure Rentien, Michaël Lévy, Christiane Copie-Bergman, Charlotte Gagniere, Jehan Dupuis, Yann Le Baleur, Karim Belhadj, Iradj Sobhani, Corinne Haioun, Jean-Charles Delchier, Aurelien Amiot
      Digestive and Liver Disease.2018; 50(2): 181.     CrossRef
    • Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH)
      Tamara Matysiak-Budnik, Bettina Fabiani, Christophe Hennequin, Catherine Thieblemont, Georgia Malamut, Guillaume Cadiot, Olivier Bouché, Agnès Ruskoné-Fourmestraux
      Digestive and Liver Disease.2018; 50(2): 124.     CrossRef
    • Place de la radiothérapie pour les lymphomes du mucosa-associated lymphoid tissue gastriques : résultats d’une étude rétrospective
      L. Ghorbal, A. Hdiji, H. Ben Salah, F. Elloumi, M. Frikha, M. Elloumi, J. Daoud
      Cancer/Radiothérapie.2018; 22(8): 763.     CrossRef
    • Les lymphomes gastro-intestinaux
      P. Jamet, T. Matysiak-Budnik, L. Brichet, A. Ruskoné-Fourmestraux
      Oncologie.2018; 20(5-6): 107.     CrossRef
    • Radiotherapy for localized gastric mucosa–associated lymphoid tissue lymphoma: long-term outcomes over 10 years
      Yu Ohkubo, Yoshihiro Saito, Hiroki Ushijima, Masahiro Onishi, Tomoko Kazumoto, Jun-ichi Saitoh, Nobuko Kubota, Hirofumi Kobayashi, Nobuo Maseki, Yu Nishimura, Masafumi Kurosumi
      Journal of Radiation Research.2017; 58(4): 537.     CrossRef
    • Place de la radiothérapie dans la prise en charge des lymphomes malins non hodgkiniens
      L. Gastaud, B. Rossignol, F. Peyrade, D. Ré, J. Thariat, A. Thyss, J. Doyen
      Cancer/Radiothérapie.2016; 20(3): 236.     CrossRef
    • Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin
      Susann Stollberg, Daniel Kämmerer, Elisa Neubauer, Stefan Schulz, Ingrid Simonitsch-Klupp, Barbara Kiesewetter, Markus Raderer, Amelie Lupp
      Journal of Cancer Research and Clinical Oncology.2016; 142(11): 2239.     CrossRef
    • Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications
      Hyeon Woo Lim, Tae Hyun Kim, Il Ju Choi, Chan Gyoo Kim, Jong Yeul Lee, Soo Jeong Cho, Hyeon Seok Eom, Sung Ho Moon, Dae Yong Kim
      Radiation Oncology Journal.2016; 34(3): 193.     CrossRef
    • Refractory peptic ulceration following radiation therapy in primary gastric lymphoma: A report of two cases
      CHUNYAN ZENG, SHIWEN LUO, NONGHUA LV, YOUXIANG CHEN
      Oncology Letters.2015; 9(1): 63.     CrossRef
    • Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up
      Agnès Ruskoné-Fourmestraux, Tamara Matysiak-Budnik, Bettina Fabiani, Pascale Cervera, Hedia Brixi, Karine Le Malicot, Isabelle Nion-Larmurier, Jean-Fançois Fléjou, Christophe Hennequin, Laurent Quéro
      Radiotherapy and Oncology.2015; 117(1): 178.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      The Role of Radiotherapy in the Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
      Cancer Res Treat. 2014;46(1):33-40.   Published online January 15, 2014
      DOI: https://doi.org/10.4143/crt.2014.46.1.33
      Close
    • XML DownloadXML Download
    • 0
    • 1
    The Role of Radiotherapy in the Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Image Image
    Fig. 1 (A) Simulation images of two-dimensional plan for radiotherapy with anterior-posterior opposing two fields including stomach and regional lymphatic area. (B) Three-dimensional plan with dose distribution shown on adjacent visceral organs. (C) Patient with gastroptosis, which required the radiotherapy field to be much larger than usual, covering entire left kidney. (D) Follow-up abdomen computed tomography showing mild atrophy with normal parenchymal density of left kidney.
    Fig. 2 Breakdown of treatment modality by pathologic grade. Low grade (A) and low and high grade mixed (B). H., Helicoboacter; dCRT, definitive radiotherapy; PD, persistent disease; sRT, salvage radiotherapy; CTx, chemotherapy; CR, complete remission; cRT, consolidative radiotherapy; S, surgery.

    Fig. 1

    Fig. 2

    The Role of Radiotherapy in the Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Patients characteristic No. of patients (%)
    Age (yr) 53 (25-85)
    Gender
     Male vs. Female 25 (52.1) vs. 23 (47.9)
    ECOG performance score
     0 40 (83.3)
     1 8 (16.7)
    Helicobacter pylori infection
     Positive 31 (64.6)
     Negative 13 (27.1)
     Unknown 4 (8.3)
    Dominant site of lesion
     Proximal 16 (33.3)
     Distal two-thirds 32 (66.7)
    Dominant endoscopic type
     Exophytic 23 (39.0)
     Ulcerative 25 (61.0)
    Histologic grade
     Low 41 (85.4)
     Mixed with high grade component 7 (14.6)
    Clinical stage
     IE 37 (77.1)
     IIE 11 (22.9)
    Other location
     Stomach only 37 (77.1)
     Stomach+perigastric lymph nodes 9 (18.8)
     Stomach+duodenum 2 (4.1)
    Characteristic Case 1 Case 2 Case 3
    Age (yr) 78 40 52
    Gender Female Male Female
    Grade Low Low Low
    Stage IIE IE IE
    Initial Helicobacter pylori infection Yes Yes No
    H. pylori eradication Yes Yes No
    Oncologic treatment FND #3
    + RT 30.6 Gy    		 RT 30.6 Gy RT 30.6 Gy
    Response PD CR CR
    Second malignancy DLBCL+MALT DLBCL EGC/BALT
    Interval from RT to diagnosis of secondary malignancy 3 mo 38 mo 44/51 mo
    Salvage treatment R-CHOP #4 +
    + rituximab augmentation #4    		 R-CHOP #8 EMR/no treatment
    Final follow-up status NED at 31 mo NED at 64 mo Dead without MALT at 57 mo
    Table 1 Patient characteristics

    ECOG, Eastern Cooperative Oncology Group.

    Table 2 Patients who developed secondary malignances during the follow-up period

    FND, fludarabine, mitoxantrone, dexamethasone; RT, radiotherapy; PD, persistent disease; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; EGC, early gastric adenocarcinoma; BALT, bronchus-associated lymphoid tissue; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; EMR, endoscopic mucosal resection; NED, no evidence of disease.

    Table 1

    Table 2

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP